REDEFINING Liquid biopsies

Genomill’s vision is to be a leader in the transformation of precision diagnostics with the ultimate goal of enabling the full potential of liquid biopsies across the world.

Removing the barriers for global access

Genomill is a pioneering precision diagnostics company with a mission to democratize the use of liquid biopsies for oncology, infectious disease detection and beyond, by removing the barriers for global access.

We want to harness the use of the Next-Generation-Sequencing in diagnostics to the next level with our proprietary Geno1® pre-sequencing platform, enabling significant improvements in costs, performance and scalability.

Low cost

High accuracy

Massive scalability

Geno1

A novel bridge capture approach

Our proprietary and patented (US patent nr: 20220298569 and 20220298566) Geno1® technology is a unique combination of molecular biology, robotics, next-generation DNA sequencing and data interpretation.

It truly provides means for vertical progress and enables fundamental improvements in cost, accuracy, turn-around-time and scalability. It unlocks the future.

JOIN OUR JOURNEY

We’re set to saturate the scattered liquid biopsy space with our technology. We offer Geno1® for out-licensing and are continuously looking for new long-term collaboration partnerships within oncology and other verticals – infectious diseases, NIPT, antibiotic resistance.

Join us in harnessing a true game-changing technology!

Genomill team

Manu Tamminen Genomill Health

Dr. Manu
Tamminen


CTO, SCIENTIFIC

Expert in molecular biology, next-generation DNA sequencing and bioinformatics • Post-doctoral experience at MIT and ETH Zurich • Startup experience at a Harvard Medical School spin-off specializing in single cell transcriptomics

Kalle Koskinen Genomill Health

Kalle
Koskinen


CEO, COMMERCIAL

Experienced medtech & life science professional – with several years global experience in commercial functions LATAM, Switzerland, Nordics. • M.Sc Economics Sciences, M.Sc International Politics

Juuso Blomster Genomill Health

Dr. Juuso Blomster


MEDICAL ADVISOR,
QUALITY, COMMERCIAL


MD, PhD in cardiology • International experience in clinical research functions & quality • Big pharma and clinical background

Jukka Laine Genomill Health

Dr. Jukka Laine


MEDICAL ADVISOR,
CLINICAL EXPERT


Experienced pediatric pathologist • Pediatric diseases and cancer • 84 scientific publications • Associate Professor

Sami Savisalo Genomill Health

Sami Savisalo


BOARD MEMBER

Master of Laws (LL.M) • Several years experience in life science and biotech • Specialities: M&As, startups, IPR

Mike Doherty


STRATEGIC ADVISOR, BOARD MEMBER

Ex Foundation Medicine, Roche, Genentech executive

Tõnu Esko Genomill Health

Tõnu Esko


SCIENTIFIC ADVISOR

Professor of Human Genomics at University of Tartu • Head of Estonian Biobank Innovation Center • Research Scientist at Broad Institute of MIT and Harvard • Co-author in 350+ scientific publications • Among the 250 most influential scientist in the fields of molecular biology and genetics

Latest news

Genomill appoints former foundation medicine executive and plans to present unmatched data at PMWC

Genomill appoints former foundation medicine executive and plans to present unmatched data at PMWC

Seminal presentation of first analytical validation data scheduled for june 30
<font color="#4B9CD2"> Genomeweb: </font> Genomill Health Positioning Geno1 Technology to Improve Liquid Biopsy Sequencing

Genomeweb: Genomill Health Positioning Geno1 Technology to Improve Liquid Biopsy Sequencing

 NEW YORK – After closing an investment round last month for an undisclosed sum, Finnish firm Genomill Health is aiming…
Genomill Health closes investment round to expand beta-testing with liquid biopsy players

Genomill Health closes investment round to expand beta-testing with liquid biopsy players

Genomill Health closes a financing round led by a deep tech VC Voima Ventures to expand its novel and disruptive…